June 14, 2019 — Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical candidate, firibastat, in patients with heart failure after acute myocardial infarction (AMI). Firibastat is a first-in-class brain aminopeptidase A inhibitor, being developed for the treatment of resistant hypertension and heart failure.
Gilles Montalescot, M.D., Ph.D., lead investigator of the QUORUM trial, commented, “Despite some medical breakthroughs in healthcare throughout the last decade, mortality rate due to heart failure remains high, with about 50 percent of patients diagnosed dying within five years. The initiation of this trial is an important step forward in potentially providing the millions of patients who suffer from heart failure a novel therapy to address their significant unmet needs.”
QUORUM (QUantum Genomics QCG001 Or Ramipril after acUte Myocardial infarction to prevent left ventricular dysfunction) is a multi-center, multinational, randomized, double-blind, active-controlled trial with three parallel groups (firibastat 100 mg BID, firibastat 500 mg BID and ramipril 5 mg BID). The study will enroll 294 subjects within 72 hours after AMI who have been treated with primary percutaneous coronary intervention (PCI). The aim of the study is to assess the efficacy and the safety of firibastat compared to ramipril.
The primary endpoint will be the change from baseline in left ventricle ejection fraction (LVEF) assessed by cardiac magnetic resonance (CMR) after a three-month treatment. Other endpoints will include cardiac events, functional status, safety and change in HF biomarkers.
For more information: www.quantum-genomics.com
November 18, 2024 
